Randomized Study of Docetaxel +/- Vandetanib in Metastatic TCC
Status:
Completed
Trial end date:
2015-05-01
Target enrollment:
Participant gender:
Summary
In this research study the investigators are looking to see if the combination of docetaxel
plus Vandetanib is effective in the treatment of metastatic transitional cell carcinoma
(TCC). Docetaxel is a chemotherapy drug that kills cancer cells that are dividing. It is
widely used in TCC. Vandetanib is a drug that is believed to stop new blood vessels from
forming around cancer cells. The combination of docetaxel and Vandetanib has been studied in
people with lung cancer and found to be helpful in killing cancer cells. Thus, this study is
looking at people with TCC, to see if the combination of docetaxel plus Vandetanib is better
or worse then docetaxel alone.
Phase:
Phase 2
Details
Lead Sponsor:
Dana-Farber Cancer Institute
Collaborators:
AstraZeneca Beth Israel Deaconess Medical Center Brigham and Women's Hospital Massachusetts General Hospital